US Futures Rebound as Markets Await Pivotal Q4 GDP Growth Data

The pre-market activity on Friday reflects a classic recalibration as Wall Street prepares for one of the most significant economic data points of the quarter: the Q4 GDP report. After a period of volatility where investors grappled with mixed earnings and shifting interest rate expectations, the GDP print serves as a definitive scorecard for the U.S. economy's health. The slight uptick in Dow and S&P 500 futures suggests a cautious optimism that the "Goldilocks" scenario—growth that is strong enough to avoid recession but not so hot as to reignite inflation—remains intact.

The focus on GDP comes at a critical juncture for the Federal Reserve. If the data shows a robust expansion, it may provide the central bank with more leeway to maintain higher rates for longer, a prospect that has historically pressured growth-oriented sectors. Conversely, a significant miss could revive fears of a slowdown, though it might also accelerate the timeline for potential rate cuts. This tension is currently the primary driver of price action in the SPDR S&P 500 ETF Trust (SPY), which remains the benchmark for broader market sentiment and a primary vehicle for institutional hedging ahead of major data releases.

“

Simultaneously, Candel Therapeutics (CADL) has moved into the spotlight following the pricing of a substantial $100 million public offering.

In the healthcare and biotech sectors, Grail (GRAL) is navigating a complex narrative that underscores the high-stakes nature of clinical development. While the company reported a beat on both top and bottom lines for its fourth-quarter and full-year 2025 results—posting revenue of $43.6 million—the stock is facing significant headwinds from clinical trial data. The landmark NHS-Galleri trial failed to meet its primary endpoint of showing a significant reduction in stage III and IV cancer diagnoses. Although the trial demonstrated a four-fold higher detection rate for certain cancers and increased early-stage detection, the failure to hit the primary mortality-linked metric has introduced uncertainty regarding the long-term regulatory and commercial path for its multi-cancer early detection test.